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Objective: Single-lung transplantation is an accepted treatment for end-stage lung
disease caused by chronic obstructive pulmonary disease. A complication unique to
single-lung transplantation for chronic obstructive pulmonary disease is graft dys-
function due to compression caused by native lung hyperinflation. We hypothesized
that patients with functional compromise from native lung hyperinflation would
benefit from native lung volume reduction surgery.
Methods: The charts of all patients undergoing single-lung transplantation for chronic
obstructive pulmonary disease were reviewed for lung volume reduction surgery of
their native lung. Data regarding length of stay, surgical morbidity and mortality,
overall survival, type of lung volume reduction surgery, and pulmonary function
were recorded to evaluate the effect of lung volume reduction surgery.
Results: Between February 1992 andMay 2007, 206 single-lung transplantations were
performed for chronic obstructive pulmonary disease. Ten (5%) patients had clinically
significant graft compression from native lung hyperinflation. After excluding other
causes for functional decline, these patients underwent a modified lung volume reduc-
tion surgery between 12 and 142 months after single-lung transplantation (mean, 50
months). Lung volume reduction surgery consisted of anatomic resection. Two
(20%) of 10 patients died during their hospitalization. Of the remaining 8 patients, 7
(87.5%) have demonstrated functional improvement on the basis of forced expiratory
volume in 1 second improving from 12% to 200% (mean improvement, 57%). Within
6 months of lung volume reduction surgery, mean 6-minute walk values improved sig-
nificantly (866 to 1055 feet), whereas desaturationwith exertion decreased significantly.
Conclusions: Lung volume reduction surgery by means of formal lobectomy in
patients with native lung hyperinflation undergoing single-lung transplantation and
significant graft compression appears feasible. Additionally, improvements in forced
expiratory volume in 1 second can be accomplished in nearly all properly selected
patients. Lung volume reduction surgery should be considered in patients with de-
creasing graft function caused by graft compression from native lung hyperinflation.
S
ingle-lung transplantation (SLT) is an accepted treatment for end-stage lung
disease caused by chronic obstructive pulmonary disease (COPD). SLT for
COPD has accounted for almost 40% of lung transplantations according to
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TXAbbreviations and Acronyms
BOS 5 bronchiolitis obliterans syndrome
COPD 5 chronic obstructive pulmonary disease
CT 5 computed tomography
FEV1 5 forced expiratory volume in 1 second
LVRS 5 lung volume reduction surgery
NLH 5 native lung hyperinflation
SLT 5 single-lung transplantation
the most recent report from the International Society for
Heart and Lung Transplantation Registry.1 Moreover, from
1995 through 2005, more than 67% of lung transplantations
for COPD were single-lung rather than double-lung trans-
plantations.
A complication unique to SLT for COPD is graft dysfunc-
tion due to compression caused by native lung hyperinflation
(NLH).2 Clinically relevant graft compression is character-
ized by a decrease in clinical function as measured by a de-
crease in forced expiratory volume in 1 second (FEV1),
exercise tolerance, and increased oxygen requirements in
the setting of radiographic evidence of graft compression.
Lung volume reduction surgery (LVRS) has been proposed
as a method of treatment for this phenomenon.3-7 Table 1
summarizes the most comprehensive reports in the literature
on lung volume reduction surgery after single lung trans-
plants for COPD.
The purpose of this study was to determine whether native
lung resection improves overall lung function in the setting of
transplant graft compression caused by NLH. We hypothe-
sized that patients with graft compromise caused by NLH
would benefit from LVRS of the native lung. This study
reports our experience in 10 patients undergoing LVRS for
NLH and graft compression after SLT for COPD.
Materials and Methods
Approval of this study was obtained from the Colorado Multiple
Institutional Review Board. The charts of all patients undergoing
SLT for COPD at our institution between February 1992 and May932 The Journal of Thoracic and Cardiovascular Surgery c Apr2007 were reviewed to capture those patients undergoing LVRS
for SLT graft compression. Functional decline was defined primar-
ily as a decrease in FEV1, but a decrease in 6-minute walk values and
an increase in the need for supplemental oxygen also contributed to
this determination. Graft compression was suspected with chest
radiographic findings of progressive mediastinal shift (Figure 1).
Chest computed tomography (CT) was used to confirm mediastinal
shift in the setting of an incremental decrease in transplanted lung
volume. Other CT findings included evidence of compression of
the intragraft vasculature or a large bronchus. Patients underwent
bronchoscopy with transbronchial biopsy to rule out airway stenoses
or bronchomalacia or acute or chronic rejection. A careful evalua-
tion was performed to rule out other causes of decreased allograft
function, as shown in Figure 2. The modified LVRS consisted of
anatomic resections, both lobectomy and segmentectomy, rather
than the more traditional extensive buttressed wedge resections.
Data were recorded regarding outcomes of LVRS, including
length of hospital stay, perioperative morbidity, and mortality.
Date and timing of both the original transplantation and the LVRS
were noted. Furthermore, the patient’s overall survival and specific
LVRS procedure were reviewed. Most importantly, pulmonary
function test results were recorded from evaluation for transplanta-
tion to the present. The patients’ FEV1, 6-minute walk values, and
oxygen requirements were used as objective markers to determine
the overall effect of LVRS procedure by comparing them at their
peak after transplantation, before LVRS, and postoperatively after
LVRS.
Statistical comparisons were performed by an independent stat-
istician using repeated-measures analysis of variance, and differ-
ences were confirmed with Tukey HSD multiple-comparison
analysis.
Results
From 404 lung transplantations, 206 SLTs were performed
for COPD. Ten (5%) patients experienced significant func-
tional graft compression and underwent LVRS. All patients
underwent a modified LVRS consisting primarily of ana-
tomic resections, as follows: 3 lower lobectomies, 5 upper lo-
bectomies, a bilobectomy, and a lower lobe segmentectomy
with upper lobe wedge resection. Three of the 10 patients
also underwent intercostal muscle flap reinforcement of the
bronchus. All LVRSs were performed by one of 3 surgical
staff whose practice consists solely of thoracic surgery.TABLE 1. Reported literature on native lung volume reduction surgery after single-lung transplantation





Kroshus and coworkers6 1996 3 NLH LVRS 100% 1/3
Anderson and coworkers3 1997 3 NLH LVRS 100% Not reported
Schulman and coworkers12 1999 7 BOOP LVRS 86% 3/7
Fitton and coworkers11 2003 5 NLH LVRS NA 2/4
Current study 2007 10 NLH Lobectomy 70% 8/10
Most reports are small, demonstrating at least early functional improvement. These studies include all reports with more than 1 patient. The larger studies
show that longer-term outcomes can be mixed, which stresses the importance of patient selection for this procedure. LVRS, Traditional lung volume reduction
surgery with extended, buttressed wedge resection of the native lung; NLH, native lung hyperinflation; BOOP, bronchiolitis obliterans organizing pneumonia.il 2008
Reece et al Cardiothoracic TransplantationFigure 1. Evolution of graft compression on chest radiographic analysis. These plain films show the progression of
graft compression with increased right lung volume and mediastinal shift from after transplantation to before lung
volume reduction surgery (LVRS). The last film demonstrates resolution of the compression after LVRS.TXThe mean time between transplantation and LVRS was 50
months (range, 12–142 months). The decrease in FEV1
between SLT and LVRS was 40% (range, 11%–70%) from
transplantation to consideration for LVRS. Two patients
died in the perioperative period at 17 and 34 days, respec-
tively, after the operation. One death stemmed from bron-
chial stump complications, whereas the other patient was
ultimately found to have bronchiolitis obliterans syndrome
(BOS) on autopsy. Two other patients required reintubation
during their hospital course. Three patients had postoperative
pneumonia, 2 cases of which resulted in hospital deaths. Five
had prolonged air leak of greater than 7 days. One patient had
acute renal failure requiring hemodialysis. The intensive care
unit stay averaged 13 days (range, 4–34 days). Hospital stay
averaged 18 days (range, 8–34 days) after LVRS.
Follow-up of the survivors from LVRS averaged 21
months (range, 9–71 months). After discharge, all patients
except 1 were still alive, with the 1 late death being a result
of complications from posttransplantation lymphoprolifera-
tive disease. Of the 8 patients who left the hospital, 7
(87.5%) demonstrated significant functional recovery, as
shown by improvement of FEV1 to the previous baseline
value (Figure 3). FEV1 improvement averaged 57% (range,
12%–200%). Improvement in FEV1 surpassed the previous
posttransplantation peak in 1 patient. Among hospital survi-
vors, 7 of 8 patients desaturated with exertion (decrease of
4% or to ,90%) before LVRS, but none of the 8 decreased
their oxygen saturation with exercise at their peak after trans-
plantation. After LVRS, only 2 of 8 patients desaturated with
exertion. Additionally, the impaired 6-minute walk values of
these patients demonstrated s significant reduction from theirThe Journal of Thopeak after transplantation to the time of LVRS, with a return
to baseline around 6 months after LVRS. Finally, mean oxy-
gen saturation was 94.5% at rest after transplantation. This
decreased significantly to 90% before LVRS, with significant
Figure 2. Algorithm for lung volume reduction surgery (LVRS) after
single-lung transplantation for chronic obstructive pulmonary dis-
ease. The steps for working up a decrease in pulmonary function
in single-lung transplantation for chronic obstructive pulmonary
disease are shown. native lung hyperinflation (NLH) is a diagnosis
of exclusion, and therefore every attempt is made to exclude in-
fection, acute rejection, and bronchiolitis obliterans syndrome
(BOS). The workup, in bold, includes findings and reasons for
the test. FEV1, Forced expiratory volume in 1 second; CXR, chest
radiography; VQ, ventilation/perfusion.racic and Cardiovascular Surgery c Volume 135, Number 4 933
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TXrecovery to 93.4% after LVRS. The results of the 6-minute
walk and resting peripheral oxygen saturation measurements
are depicted in Figure 4. The specific procedures and out-
comes of each patient are summarized in Table 2.
Discussion
Although the optimal approach to end-stage COPD is argued,
the International Society for Heart and Lung Transplantation
Registry demonstrates that SLT for COPD has been the most
Figure 3. Changes in forced expiratory volume in 1 second (FEV1).
The graft depicts individual changes in FEV1 from after transplan-
tation to after LVRS by each patient. On average, there was signif-
icant improvement, and all but 1 of the hospital survivors
demonstrated benefit on the basis of FEV1 from the procedure.
The mean FEV1 at each point is depicted by the thick gray line
with the diamond markers. *Significant change from after trans-
plantation and after lung volume reduction surgery (LVRS; P< .01).934 The Journal of Thoracic and Cardiovascular Surgery c Aprcommon lung transplantation procedure performed.1 The
native lung in these patients can continue to overinflate,
which does not usually affect overall pulmonary function.
However, a small subset of these patients has compromised
function of the transplanted lung as a result of compression
by the native lung. This transplant lung compression can
manifest with increased oxygen requirements, deterioration
in pulmonary function tests, and significant reduction in
exercise capacity. The algorithm used for evaluating these
patients for LVRS is depicted in Figure 2. Although all
patients are followed with serial chest radiography, chest
CT scans can facilitate diagnosis in these patients, with dem-
onstration of increasing native lung expansion at the cost of
allograft volume. Other CT findings included evidence of
compression of the intragraft vasculature or a large bronchus.
Patients underwent bronchoscopy to rule out airway stenoses
or bronchomalacia and transbronchial biopsies to evaluate
for acute or chronic rejection. It is critical that chronic rejec-
tion or BOS is ruled out before LVRS because patients with
BOS do very poorly with lung surgery. This might not always
be possible, but the lack of a mosaic pattern or air trapping on
CT scanning or patchy perfusion defects on perfusion scinti-
graphic analysis suggest the absence of BOS.8,9
The National Emphysema Treatment Trial showed that
resection of focal areas of emphysematous lung can benefit
select patients with COPD.10 LVRS is intended to relieve
compression of more normal areas of lung through resection
of the most diseased, least functional areas of the lung. This
was shown to be most effective in patients with relatively fo-
cal disease (upper lobe predominant). In regard to the current
study, all the patients have focal COPD limited to their native
lung but were not believed to be LVRS candidates before
transplantation. Similar to traditional LVRS, the mostFigure 4. Changes in pulmonary function: A,
changes in 6-minute walk values; B, changes in
room air oxygen saturation. These 2 graphs
show the respective changes in mean distance
during 6-minute walks and room air oxygen from
after transplantation through the clinical native
lung hyperinflation to after lung volume reduction
surgery (LVRS). Both markers of clinical pulmo-
nary function showed a decrease from peak after
transplantation, which was recovered to baseline
in the majority of patients within 6 months of
LVRS. *Significant change from after transplanta-
tion and after LVRS, P < .01).il 2008









47* F 108 COPD RLL 17 Prolonged air leak,
pneumonia, death
NA NA 0.5
49 F 45 COPD RUL 21 Prolonged air leak 130% 114% 8
50* F 12 a1-Antitrypsin LLL 34 MSOF, death NA NA 1
54 F 37 COPD RUL, RML 16 Pneumonia, ileus 1200% 166% 16
54 M 142 COPD RUL 26 Prolonged air leak,
reintubation
1100% 118% 14
55 F 23 COPD LUL 10 None 112% 130% 9
55 M 41 COPD RUL bleb,
RLL segment
11 Pain control 150% 210% 18
59 F 54 COPD RLL 11 Prolonged air leak 133% 150% 70
61 M 37 COPD LUL 26 ARF, reintubation 230% 132% 11
61y M 22 COPD LUL 8 Prolonged air leak 157% 133% 18
Specific patient outcomes after lung volume reduction surgery for native lung hyperinflation causing transplant graft compression in patients with single-lung
transplantation for chronic obstructive pulmonary disease are shown. SLT, Single-lung transplantation; LVRS, lung volume reduction surgery; Dx, diagnosis;
LOS, length of hospital stay; FEV1, forced expiratory volume in 1 second; COPD, chronic obstructive pulmonary disease; RLL, right lower lobectomy; RUL, right
upper lobectomy; LLL, left lower lobectomy;NA, not applicable;MSOF, multiple systems organ failure; RML, right middle lobectomy; LUL, left upper lobectomy;
Bleb, blebectomy; ARF, acute renal failure. *Hospital death. yLate death.TXhyperinflated lobe or lobes of the native lung were targeted
for resection in the present study.
Lung resections in patients undergoing lung transplanta-
tion are considered high risk for almost all patients. Pulmo-
nary resection for these patients might be at even higher
risk given the combination of immunosuppression and an
extremely abnormal native lung. However, there is a growing
body of literature documenting the feasibility of operating on
these patients. Fitton and colleagues11 published a series of
12 lung resections performed on lung transplant recipients
for various indications, including graft compression, infec-
tion, and neoplasm. Overall, their high-risk cohort did rela-
tively well, with 85% surviving a month. Of note, the
subgroup undergoing wedge resection did notably worse. A
proposed mechanism is that these patients would have diffi-
culty healing the long suture line of a wedge resection. They
conclude that with medical optimization, lung resections in
lung transplant recipients is high risk but can be undertaken
with acceptable morbidity and chance for success. Other
reports in the literature substantiate the feasibility of lung
resections after lung transplantation.3,4
Several smaller series of LVRS in patients undergoing
lung transplantation have been published, but they include
limited data regarding outcome beyond a year of follow-
up.3-7 Case reports of lung resections for NLH can be found
back to 1996. These reports include both lobectomies and
wedge resections. Schulman and associates12 reported using
LVRS with disabling BOS. They performed a more tradi-
tional LVRS with native lung wedge resection. In their study
the majority of patients showed some improvement in pulmo-
nary function with relief of allograft compression. Although
they found native lung LVRS for BOS salvaged some respi-The Journal of Thorratory function, the benefits were concluded to be limited in
magnitude and duration by the severity of the chronic rejec-
tion. They reported that 3 of 7 reported patients died within
a year of their procedure after LVRS, despite documented
early improvements in pulmonary function. Fitton and
colleagues11 reported 4 native lung reductions for NLH in
their report on lung resections in patients undergoing lung
transplantation. Of the remaining 2 patients, one lived for
more than 3 years after LVRS, and the other was still alive
more than a year out at the time of their publication. These
studies demonstrate that LVRS is feasible in patients
undergoing lung transplantation but that patient selection,
in particular avoiding operations in patients with BOS, and
timing of surgical intervention are probably the most impor-
tant determinants of longer-term postoperative outcomes for
these patients.
The present series represents the largest series of native
lung LVRS in SLT for COPD found in the literature. The
development of NLH leading to clinically significant allo-
graft compression has been uncommon, with 10 patients
undergoing native lung LVRS among 206 SLTs for COPD.
Overall, patients undergoing LVRS for NLH faired well in
our study. Two patients died during their hospital course,
which is consistent with the National Emphysema Treatment
Trial mortality rate for LVRS in nonimmunosuppressed pa-
tients.2 The development of pneumonia was a difficult prob-
lem for these patients to overcome because the 2 deaths both
included pneumonia. One of these 2 patients with pneumonia
was found later to have BOS, which complicated the pulmo-
nary course. One patient who had pneumonia during the
hospital course left the hospital. Seventy percent of the
patients enjoyed functional improvement on the basis ofacic and Cardiovascular Surgery c Volume 135, Number 4 935
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algorithm depicted in Figure 2, patients can be well selected
for LVRS to possibly reset the baseline of their pulmonary
function to their peak after transplantation. This reestablish-
ment of baseline lung function has been demonstrated by
improved 6-minute walk values, oxygen requirements,
room air saturations at rest, and FEV1.
Given the less-than-optimal reports of both wedge resec-
tions and traditional LVRS in the SLT literature, anatomic
resections were chosen in an effort to facilitate pulmonary
healing. This strategy appears to have been successful, but
prolonged air leak still occurred in half of the patients and sig-
nificantly extended hospital stays. The extended hospital
stays and incidence of complications demonstrate the level
of care needed for these patients. Although intense pulmo-
nary rehabilitation was required for recovery from their
lung resections, 7 of 8 patients discharged from the hospital
saw improved pulmonary function, as demonstrated by their
improved FEV1. In terms of late follow-up, 7 of 8 hospital
survivors are alive at a mean of 20 months after LVRS.
These data demonstrate that LVRS by means of formal
anatomic resection in patients undergoing SLT with signifi-
cant graft compression from NLH is feasible. Although
hospital stay and pulmonary rehabilitation can be intensive,
improvements in lung function can be accomplished in nearly
all properly selected patients, with excellent long-term sur-
vival. In conclusion, LVRS should be considered in patients
with decreasing graft function caused by graft compression
from NLH.
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Discussion
Dr Patricia Thistlethwaite (San Diego, Calif). I would like to con-
gratulate Dr Reece and his colleagues at the University of Colorado
for an excellent presentation and a well-written article. This is
indeed a difficult set of patients to manage, those with overinflation
of a native lung compromising transplant allograft function. It is nice
to see that your surgical approach, first described by our group at the
University of California at San Diego in 1996 in the SLT patient
population with emphysema, is still being effectively used to this
day. I think many of us would agree that LVRS after lung transplan-
tation is performed as a last resort, when allograft deterioration
occurs and the CT scan shows compression of the transplant lung.
This is reflected by the high-risk stakes of doing this operation
seen by the fact that you had a 20% perioperative mortality and
that most patients had long intensive care unit and hospital stays. I
am surprised that you chose thoracotomy over thoracoscopy in
this immunocompromised and pulmonary compromised set of pa-
tients. Newer technologies, such as the use of 1-way endobronchial
valves and the trend of performing double-lung transplantations in
patients with COPD and a1-antitrypsin disease, might eliminate
the need for LVRS in these subsets of patients who have transplan-
tations in the future. I have several questions.
First, most cases of SLT for emphysema show some degree of
hyperinflation of the native lung from the beginning with the first
postoperative chest radiograph. What is your threshold for surgical
intervention, and are there specific CT scan measurements of medi-
astinal shift that you could retrospectively identify as being useful to
determine who would benefit from this operation and when inter-
vention should occur?
Dr Reece.We have not applied any kind of volumetric analysis
at this point. We have not been able to apply the technology, and our
patients do not generally get a CT scan repeatedly unless there is
a problem. Chest radiography is the way that we most commonly
follow them, and unfortunately, the CT scans that we order are usu-
ally because of another problem, such as infection or concern about
bronchiolitis; therefore it has been hard to define any CT criteria
alone that would push us to do an LVRS.
Dr Thistlethwaite. Thank you. Most of your patients underwent
LVRS in a time frame when chronic rejection is common. When do
you decide that symptoms are due to allograft compression rather
than rejection? We know that there is no reliable CT scan finding
that is pathognomonic for chronic rejection. There is also well-docu-
mented sampling error and pathologic grading variability in the di-
agnosis of chronic rejection that might obscure why these patients
have progressive shortness of breath. Were they empirically treated
for chronic rejection before LVRS? (end cassette side)ril 2008
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TXDr Reece.. from reviewing their charts. None of these patients
were treated preoperatively. We hope that our algorithm rules out
the majority of the patients who are having chronic rejection or hav-
ing other problems besides NLH. As shown by one of our 2 deaths,
we actually missed it in that patient. I think it is a difficult call to
make, but given all of the clinical information, we have been able
thus far to make a good judgment of who has bronchiolitis and
who does not. It is definitely a problem that we have seen clinically
and something that we try to avoid and have not been able to elim-
inate completely.
Dr Thistlethwaite. Yes, in our group it seems to almost always
be a concurrent problem.
Finally, and probably most importantly, in your cohort of
patients, did LVRS result in permanent relief from NLH, or was it
temporary? If so, for how long?
Dr Reece. It looks like the patients take around 6 months or so to
recover to a peak after their LVRS, but they do have some gradual de-
crease thatwe see in all of the patients undergoing lung transplantation.
We do think thatwe reset their baseline, but it is not a cure-all for future
deterioration. It seems to be something that can reset their baseline and
allow them toget back to a pointwhere they are feelinggood anddoing
the things that they need to and continue along with their lives.
Dr Thistlethwaite. Thank you very much, and I would like to
thank the Association for the privilege of the floor.
Dr Michael Mulligan (Seattle, Wash). I applaud your desire to
weigh in with this population. This is a topic that has been discussed
by revered colleagues who have condemned it as being fairly useless
and inappropriate. Your data are very encouraging, even though the
mortality and morbidity appear to be quite high. My question to you
is this:Who pays for this? The overwhelming majority of payers will
not reimburse unilateral LVRS, yet you are here telling us that this is
indeed LVRS. A bullectomy can be reimbursed as a unilateral proce-
dure, but for patients about whom we have made ongoing solicita-
tions to try and get reimbursement, we have been shut down. Who
is paying for it, and how are you coding it to get it paid for?
Dr Reece. I am not certain about that. I have no idea about the
coding or reimbursement at this point, but I will look into it and
get back to you.
Dr Robert Cerfolio (Birmingham, Ala). We are coding it as bul-
lectomy. That is a very important point. That is how we list it, and
that iswhat I think it really is, notLVRS.Wehave done several of these
at Birmingham, and I want you to takeme on your cognitive leap from
doing a large wedge resection to doing a lobectomy. I think one of the
deaths was from a bronchopulmonary fistula, which you could have
avoided. Second, yourmain problemwas prolonged air leaks.Nomat-
ter whether you do a fissureless lobectomy like most of us do, where
one staples the fissure last and takes all of the vessels and bronchus
first, or not, it is the large space that helps prevent sealing of the leaks.
There is a lack of parietal to visceral pleural apposition. Therefore why
perform an anatomic operation for a problem that does not require one
and leads to a larger space deficit?Why not do a wedge resection, like
we do in bullectomy surgery or in LVRS? Thus I have done all these
with LVRS-type techniques, using pericardially buttressed staple
lines, pleural tents, and justwedges. Iwouldnot do a lobectomy,where
a stump is at risk, especially in an immunocompromised patient.
Therefore tell me again why I should follow your cognitive leap of do-
ing a lobectomy instead of just a large wedge resection.The Journal of ThorDr Reece. I think there are some data, although I would have to
acknowledge that they are few, that patients with lung transplanta-
tions who get wedge resections—which LVRS is going to be an
extended wedge resection—do worse. I mean, there is nothing to
validate that, but we believe that if we have a small staple line of
a bronchus and hopefully a smaller one of less tissue within the
fissure itself, we would decrease the amount of air leaks from the
lung parenchyma itself.
Dr Ross Bremner (Phoenix, Ariz). Most of your patients, or all
of your patients, have chronic problems. I wonder with your expe-
rience nowwhat your guidelines are for doing this in an acute setting
in which you get one lung only offered, and when the lung comes to
you, it is a little smaller than you had hoped for, or in the setting in
which in the first couple of days after the operation you are having
a lot of trouble with NLH on the vent.
Dr Reece.We have actually published on NLH in the acute set-
ting, and with thoughtful management, we were able to get beyond
this, so that it does not cause an increase in mortality and it does not
cause an increase in morbidity, but I think this is a completely dif-
ferent subject from the chronic NLH that we are dealing with
here. There are reports in the literature of surgeons doing bullecto-
mies or lobectomies at the same time that they are doing the opposite
lung transplantation, but that would subject many patients to a super-
fluous procedure for a process that would be unlikely to lead to an
eventual compromise in pulmonary function. In our opinion, the
low incidence of significant NLH does not justify prophylactic con-
tralateral resection.
Dr RichardWhyte (Stanford, Calif). I enjoyed your article, and
I think it is very nice to have some data on what happens with these
patients because many of us who have been involved with lung
transplantations have been asked to do this operation in patients
over the years, and now we kind of know what happens. Interest-
ingly, you can use the results to justify whichever approach, whether
you want to do it or not.
My question relates to how you exclude bronchiolitis obliterans,
which is actually a diagnosis of exclusion itself, yet you seem to be
able to eradicate or eliminate those that you think have bronchiolitis
obliterans. In fact, with your deaths, you had a 50% error rate. How
do you eliminate a diagnosis of exclusion?
Dr Reece. That is a good question. I would have to lean on our
pulmonary colleagues, as well as the pathologists, and all come to-
gether with a conclusion of whether we all believe that they have
bronchiolitis. I do not know whether I can quantify how we say
they do not at this point, but we have been fairly lucky and success-
ful in avoiding it in all but 1 patient.
Dr Thistlethwaite. Dr Reece, I have one last question. Do
you have a similar cohort of patients in whom you have actually
chosen to do a contralateral retransplantation instead of lung re-
duction? Do you have any comparisons between the 2 groups? If
one looks at this, all of these patients would likely be candidates
for retransplantation of the contralateral native lung, and when
you see the morbidity and mortality of LVRS, one could argue
that the morbidity and mortality of retransplantation would po-
tentially be less, with potentially more benefit. Have you tried
that, and do you have any comparison data to tell us about?
Dr Reece. I have not looked at that, but that would definitely be
something I would like to look at in the future.acic and Cardiovascular Surgery c Volume 135, Number 4 937
